Assessing discrimination of nicotine in humans via cigarette smoking

Nicotine and Tobacco Research

Volumn 18, Issue 9, 2016, Pages 1830-1836

  Perkins, Kenneth A ^a   Kunkle, Nicole ^a   Michael, Valerie C ^a   Karelitz, Joshua L ^a   Donny, Eric C ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DISCRIMINATION TEST; DSM-5; FEMALE; HUMAN; HUMAN EXPERIMENT; INTEROCEPTION; MALE; NICOTINE DISCRIMINATION TEST; PILOT STUDY; PRIORITY JOURNAL; REINFORCEMENT; RELIABILITY; SMOKING; STRUCTURED INTERVIEW; TOBACCO DEPENDENCE; DECISION MAKING; DISCRIMINATION LEARNING; DOSE RESPONSE; DRUG EFFECTS; PREVENTION AND CONTROL; PROCEDURES; PSYCHOLOGY; SMOKING CESSATION; YOUNG ADULT;

ADULT; CHOICE BEHAVIOR; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NICOTINE; REINFORCEMENT (PSYCHOLOGY); SMOKING; SMOKING CESSATION; YOUNG ADULT;

EID: 84988822573     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntw082     Document Type: Article

References (54)

1. Harvey DM, Yasar S, Heishman SJ, et al. Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacol. 2004;175:134-142. doi:10.1007/s00213-004-1818-6.
2. Rose JE, Behm FM, Westman EC, et al. PET studies of the influences of nicotine on neural systems in cigarette smokers. Amer J Psychiatry. 2003;160:323-333. doi:http://dx.doi.org/10.1176/appi.ajp.160.2.323.
3. Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacol. 1995;117:2-10. doi:10.1007/BF02245088.
4. Glennon RA, Young R. Drug Discrimination: Application to Medicinal Chemistry and Drug Studies. New York, NY: John Wiley & Sons; 2011.
5. Smith JW, Stolerman IP. Recognising nicotine: the neurobiological basis of nicotine discrimination. In: Henningfield JE, London E, Pogun S, eds. Nicotine Psychopharmacology. New York, NY: Springer-Verlag; 2009:295-333.
6. Fischman MW, Foltin RW. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict. 1991;86:1563-1570 doi:10.1111/j.1360-0443.1991.tb01749.x.
7. Perkins KA, Jetton C, Keenan J. Common factors across acute subjective effects of nicotine. Nicotine Tob Res. 2003;5:869-875. doi:10.1080/1462 2200310001614629.
8. Preston KL, Bigelow GE. Subjective and discriminative effects of drugs. Behav Pharmacol. 1991;2:293-313.
9. Perkins KA, Sayette M, Conklin CA, Caggiula AR. Placebo effects of tobacco smoking and other nicotine intake. Nicotine Tob Res. 2003;5:695-709 doi:10.1080/1462220031000158636.
10. Holtzman SG. Discriminative stimulus effects of drugs: relationship to potential for abuse. In: Modern Methods in Pharmacology Vol 6. Testing and Evaluation of Drugs of Abuse. New York, NY: Wiley-Liss, Inc; 1990:193-210.
11. O'Dell LE, Khroyan TV. Rodent models of nicotine reward: what do they tell us about tobacco abuse in humans? Pharmacol Biochem Behav. 2009;91:481-488. doi:10.1016/j.pbb.2008.12.011.
12. Stolerman IP. Inter-species consistency in the behavioural pharmacology of nicotine dependence. Behav Pharmacol. 1999;10:559-580.
13. Perkins KA, Sanders M, Fonte C, et al. Effects of central and peripheral nicotinic blockade on human nicotine discrimination. Psychopharmacol. 1999;142:158-164. doi:10.1007/s002130050875.
14. Pich EM, Pagliusi SR, Tessari M, Talabot-Ayer D, vanHuijsduijnen RH, Chiamulera C. Common neural substrates for the addictive properties of nicotine and cocaine. Science. 1997;275:83-86. doi:10.1126/science.275.5296.83.
15. Perkins KA, DiMarco A, Grobe JE, Scierka A, Stiller RL. Nicotine discrimination in male and female smokers. Psychopharmacol. 1994;116:407-413 doi:10.1007/BF02247470.
16. Preston KL, Bigelow GE. Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose. Behav Pharmacol. 1998;9:533-543.
17. Hammond D, Fong GT, Cummings KM, Hyland A. Smoking topography, brand switching, and nicotine delivery: results from an in vivo study. Cancer Epid Biomarkers Prev. 2005;14:1370-1375. doi:10.1158/1055-9965.EPI-04-0498.
18. Pomerleau OF, Pomerleau CS, Rose JE. Controlled dosing of nicotine: a review of problems and progress. Ann Behav Med. 1989;11:158-163.
19. Benowitz NL, Hall SM, Herning RI, Jacob P, Jones RT, Osman A-L. Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med. 1983;309:139-142. doi:10.1056/NEJM198307213090303.
20. St. Charles FK, Kabbani AA, Borderding MF. Estimating tar and nicotine exposure: human smoking versus machine generated smoke yields. Reg Tox Pharmacol. 2010;56:100-110. doi:10.1016/j.yrtph.2009.08.011.
21. Marian C, O'Connor RJ, Djordjevic MV, Rees VW, Hatsukami DK, Shields PG. Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies. Cancer Epid Biomarkers Prev. 2009;18:3305-3320. doi:10.1158/1055-9965.EPI-09-1014.
22. Strasser AA, Ashare RL, Kozlowski LT, Pickworth WB. The effect of filter vent blocking and smoking topography on carbon monoxide levels in smokers. Pharmacol Biochem Behav. 2005;82:320-329. doi:10.1016/j. pbb.2005.09.001.
23. Hoffmann D, Hoffman I. The changing cigarette, 1950-1995. J Toxicol Envir Health. 1997;50:307-364. doi:10.1080/009841097160393.
24. Hoffmann AC, Evans SE. Abuse potential of non-nicotine tobacco smoke constituents: acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine Tob Res. 2013;15:622-632. doi:10.1093/ntr/nts192.
25. Rose JE. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacol. 2006;184:274-285. doi:10.1007/s00213-005-0250-x.
26. Kallman WM, Kallman MJ, Harry GJ, Woodson PP, Rosecrans JA. Nicotine as a discriminative stimulus in human subjects. In: Colpaert FC, Slangen JL, eds. Drug Discrimination: Applications in CNS Pharmacology. Amsterdam, the Netherlands: Elsevier Biomedical Press; 1982:211-218.
27. Rose JE. Discriminability of nicotine in tobacco smoke: implications for titration. Addict Behav. 1984;9:189-193. doi:10.1016/0306-4603(84)90056-X.
28. Benowitz NL, Porchet H, Sheiner L, Jacob P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther. 1988;44:23-28. doi:10.1038/clpt.1988.107.
29. Duke AN, Johson MW, Reissig CJ, Griffiths RR. Nicotine reinforcement in never-smokers. Psychopharmacol. 2015;232:4243-4252. doi:10.1007/s00213-015-4053-4.
30. Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet. 2001;40:661-684. doi:10.2165/00003088-200140090-00003.
31. Perkins KA, Epstein LH, Stiller R, Jennings JR, Christiansen C, McCarthy T. An aerosol spray alternative to cigarette smoking in the study of the behavioral and physiological effects of nicotine. Behav Res Meth Instr Comput. 1986;18:420-426.
32. Perkins KA. Discriminative stimulus effects of nicotine in humans. In: Henningfield JE, London E, Pogun S, eds. Nicotine Psychopharmacology. New York, NY: Springer-Verlag; 2009:369-400.
33. Perkins KA. Chapter 15: Nicotine discrimination in humans. In: Glennon RA, Young R, eds. Drug Discrimination: Application to Medicinal Chemistry and Drug Studies. New York, NY: John Wiley & Sons; 2011:463-481.
34. Hatsukami DK, Heishman SJ, Vogel RI, et al. Dose-response effects of Spectrum Research Cigarettes. Nicotine Tob Res. 2013;15:1113-1121. doi:10.1093/ntr/nts247.
35. Strasser AA, Ashare RL, Kaufman M, Tang KZ, Mesaros AC, Blair IA. The effect of menthol on cigarette smoking behaviors, biomarkers and subjective responses. Cancer Epid Biomarkers Prev. 2013;22:382-389. doi:10.1158/1055-9965.EPI-12-1097.
36. American Psychiatric Association (APA). Diagnostic and Statistical Manual-V. Washington, DC: American Psychiatric Association; 2013.
37. Breslau N, Kilbey MM, Andreski P. DSM-IIIR nicotine dependence in young adults: prevalence, correlates and associated psychiatric disorders. Addiction. 1994;89:743-754. doi:10.1111/j.1360-0443.1994.tb00960.x.
38. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86:1119-1127. doi:10.1111/j.1360-0443.1991.tb01879.x.
39. Donny EC, Denlinger RL, Tidey JW, et al. Randomized trial of reducednicotine standards for cigarettes. N Engl J Med. 2015;373:1340-1349. doi:10.1056/NEJMsa1502403.
40. Byrd GD, Davis RA, Caldwell WS, Robinson JH, deBethizy JD. A further study of FTC yield and nicotine absorption in smokers. Psychopharmacol. 1998;139:291-299. doi:10.1007/s002130050720.
41. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
42. Blank MD, Disharoon S, Eissenberg T. Comparison of methods for measurement of smoking behavior: mouthpiece-based computerized devices versus direct observation. Nicotine Tob Res. 2009;11:896-903. doi:10.1093/ntr/ntp083.
43. Perkins KA, Karelitz JL, Giedgowd GE, Conklin CA. The reliability of puff topography and subjective responses during ad lib smoking of a single cigarette. Nicotine Tob Res. 2012;14:490-494. doi:10.1093/ntr/ntr150.
44. Gu X, Lohrenz T, Salas R, et al. Belief about nicotine selectively modulates value and reward prediction error signals in smokers. Proc Nat Acad Sci. 2015;112:2539-2544. doi:10.1073/pnas.1416639112.
45. Hasenfratz M, Jacober A, Battig K. Smoking-related subjective and physiological changes: pre-to postpuff and pre-to postcigarette. Pharmacol Biochem Behav. 1993;46:527-534. doi:10.1016/0091-3057(93)90540-A.
46. Herskovic JE, Rose JE, Jarvik ME. Cigarette desirability and nicotine preference in smokers. Pharmacol Biochem Behav. 1986;24:171-175. doi:10.1016/0091-3057(86)90333-3.
47. Chait LE, Evans SM, Grant KA, Kamien JB, Johanson CE, Schuster CR. The discriminative stimulus and subjective effects of smoked marijuana in humans. Psychopharmacol. 1988;94:206-212. doi:10.1007/BF00176846.
48. SRNT Subcommittee. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002;4:149-159. doi:10.1080/14622200210123581.
49. Perkins KA, Grobe JE, Weiss D, Fonte C, Caggiula A. Nicotine preference in smokers as a function of smoking abstinence. Pharmacol Biochem Behav. 1996;55:257-263. doi:10.1016/S0091-3057(96)00079-2.
50. Jaffe AJ, Glaros AG. Taste dimensions in cigarette discrimination: a multidimensional scaling approach. Addict Behav. 1986;11:407-413. doi:10.1016/0306-4603(86)90019-5.
51. Rees VW, Kreslake JM, Wayne GF, O'Connor RJ, Cummings KM, Connolly GN. Role of cigarette sensory cues in modifying puffing topography. Drug Alc Depend. 2012;124:1-10. doi:10.1016/j.drugalcdep.2012.01.012.
52. King BA, Dube SR, Tynan MA. Current tobacco use among adults in the United States: findings from the National Adult Tobacco Survey. Amer J Public Health. 2012;102:e93-e100. doi:10.2105/AJPH.2012.301002.
53. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. New Engl J Med. 1994;331:123-125. doi:10.1056/NEJM199407143310212.
54. Hatsukami DK, Benowitz NL, Donny E, Henningfield J, Zeller MR. Nicotine reduction: strategic research plan. Nicotine Tob Res. 2013;15:1003-1013. doi:10.1093/ntr/nts214.